Auph short interest.

Overview of financial data and news for Aurinia Pharmaceuticals Inc., Nasdaq:AUPHNov 2, 2023 · Interest income was $4.5 million at September 30, 2023 versus $1.5 million for the prior year period. Interest income was $12.4 million and $2.2 million for the nine months ended September 30 ... Short Interest. Most Shorted. Largest Increase. Largest Decrease. Calculators. Margin Calculator. ... Aurinia Pharmaceuticals (AUPH) is scheduled to report earnings on February 27, 2024.AUPH | Aurinia Pharmaceuticals by Finance Ai provides AUPH | Aurinia Pharmaceuticals short interest and earnings date annual report with insider trading history and institutional ownership breakdown.

Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: …AUPH Short Positions, Funds Shorting Aurinia Pharmaceuticals Inc ... Short Interest Funds Shorting AUPH Short Transactions Short Volume Fails to Deliver. Options . Options Chain Options Sentiment Options Flow Gamma Exposure Implied Volatility. Filings . SEC Filings - Categorized SEC Filings - Latest Press Releases Exhibits. Financials .

1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc. Coins. 0 coins. Premium Powerups Explore Gaming. Valheim Genshin Impact Minecraft Pokimane Halo Infinite Call of Duty: Warzone Path of Exile Hollow Knight: Silksong Escape from Tarkov Watch Dogs: Legion. Sports ...1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc.

Short Interest - MarketWatchAurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ...Live Short Interest data, Utilization, Cost to borrow and much more for Aurinia Pharmaceuticals Inc., Nasdaq:AUPHData Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...As a student, you need to stretch every dollar you have. The good news is there are many banks that help students grow their income by offering high interest rates on their savings.

AUPH has a market cap of $1.08bn and $400 million of cash, cash equivalents, restricted cash and investments as of October 31, 2022. In the previous quarter, the company made $55mn in revenue ...

Jan 29, 2021 · AUPH Short Interest SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER 02/12/2021 5,442,521 4,199,973 1.295847. Reply Like. Delmar Price. 26 Feb. 2021. Investing Group.

@HowIgraph @AverygraceMoore @theoriginalspa3 decreased short interest was not real good anyway as the shorts provide support. plus, even RLYP short interest rose into a buyout; it was near 20% if i remember correctly. the fact that AUPH short interest is so low actually has been baffling, but it may be that they use optionsShort Interest: 17.28M (10/31/23)Short Interest Change-0.88%: Percent of Float: 13.23%According to the issued ratings of 2 analysts in the last year, the consensus rating for Aurinia Pharmaceuticals stock is Buy based on the current 2 buy ratings for AUPH. The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00.Aurinia Pharma press release (NASDAQ:AUPH): Q3 GAAP EPS of -$0.09 beats by $0.08.; Revenue of $54.52M (-2.3% Y/Y) beats by $16.02M. Achieved European pricing and reimbursement milestone triggering ...Dec 2, 2021 · Aurinia Pharmaceuticals (AUPH) rose 17% at least partly on some take takeover speculation following comments from Novartis (NVS). Novartis reportedly said during its R&D day earlier... AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Short Interest Change. -0.88%. Percent of Float. 13.23%. Overview. Complete Aurinia Pharmaceuticals Inc. stock information by Barron's. View real-time AUPH stock price and news, along with...Aug 3, 2023 · Some thoughts on AUPH: 1. As cited, AUPH reported Lupkynis sales +46% YOY, +20% over Q1, and raised full year guidance to $150 million - $160 million, but admittedly is only scratching the surface ... Shares of Aurinia Pharmaceuticals (AUPH) have gained 13.7% over the past four weeks to close the last trading session at $8.29, but there could still be a solid upside left in the stock if short ...WebAurinia Pharmaceuticals ( NASDAQ: AUPH) has said on Monday its collaboration partner Otsuka Pharmaceutical has filed a new drug application in Japan for its drug voclosporin. Voclosporin is a ...Short interest is the volume of Aurinia Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders …Aurinia Pharmaceuticals (AUPH) Short Interest Ratio & Short Volume $8.85 -0.39 (-4.22%) (As of 03:22 PM ET) Compare Today's Range $8.77 $10.05 50-Day Range $7.13 $9.24 52-Week Range $4.07 $12.43 Volume 6.25 million shs Average Volume 2.60 million shs Market Capitalization $1.27 billion P/E Ratio N/A Dividend Yield N/A Price Target $14.00Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Aurinia Pharmaceuticals's stock. Short interest data is...

The mean of analysts' price targets for Aurinia (AUPH) points to a 59.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...Web2021-12-27 Short sale volume (not short interest) for $JMIA is 33%. http://shortvolumes.com/?t=JMIA $ERIC 56% $SOS 58% $AUPH 42% $QLGN 52%. 28 Dec 2021Web

Introduction. This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by frequency of updates, with intraday data at the top (short shares availability, short borrow fee rate), daily data (short volume, fails-to-deliver) in the middle, and the slowest updated data (short interest) at …Mar 2, 2022 · Despite upbeat remarks from its chief executive ahead of the earnings, Aurinia’s (NASDAQ:AUPH) 2022 sales guidance fell short of expectations as net revenue for the year dropped ~9% YoY to $45 ... To find anything from restaurants to clothing stores and auto repair shops in your area, just search Yelp.com. Though Yelp features information for businesses all around the world, you can narrow your search results down to a radius as shor...AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on...Institutional Owners: 318 total, 304 long only, 0 short only, 14 long/short - change of 1.92% MRQ Average Portfolio Allocation: 0.0605 % - change of -12.95% MRQ AUPH short interest is 12%. More on Aurinia. Aurinia Pharmaceuticals: Some Improvement In Topline, But A Buyout Alone Will Unlock Value; Aurinia Pharmaceuticals: All In On Lupkynis - A Tough Bet;

Aurinia Pharmaceuticals Inc AUPH shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the company announced that its ...Web

Mar 23, 2023 · For fiscal 2023, the company expects LUPKYNIS revenue to be between $120 million and $140 million, representing annual growth of 15.4% to 34.6% in terms of net product sales. While analysts expect ...

Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) dZhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 2.8% on a report that a European-based investor group is campaigning for the biotech to begin a strategic ...Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) dNov 29, 2023 · AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ... Short Interest 17.19M 11/15/23 % of Float ... Nov 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ... Aptevo Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 26,900 shares, a decline of 74.2% from the October 31st total of 104,300 shares. Based on an average daily volume of 483,200 shares, the short-interest ratio is currently 0.1 days. View Aptevo Therapeutics' Short …These revisions helped boost AUPH's consensus estimate, increasing from -$0.76 to -$0.71 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been ...TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comShort interest is the volume of POINT Biopharma Global shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 4,390,000 shares of PNT short. 5.09% of POINT Biopharma Global's shares are currently sold short. Learn More on POINT Biopharma Global's current short interest.Dec 2, 2021 · Aurinia Pharmaceuticals (AUPH) rose 17% at least partly on some take takeover speculation following comments from Novartis (NVS). Novartis reportedly said during its R&D day earlier... Aurinia Pharma press release (NASDAQ:AUPH): Q2 GAAP EPS of -$0.08 beats by $0.11.; Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...

Global Coverage. Comprehensive ownership data of US Institutions, Mutual Funds, and ETFs targeting equities and bonds in mature, emerging, and frontier markets. Activist Investor 13D Filings. Beneficial Ownership 13G Filings. Institutional Ownership 13F Filings. Insider 3, 4 and 5 Filings.WebMay 11, 2023 · AUPH is currently averaging 3,052,205 shares for the last 20 days. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Cash received for interest $ 2,713 $ 528 Cash paid for income taxes $ (277) $ (779) Cash paid for amounts included in the measurement of lease liabilities $ (531) $ (572) Supplemental disclosure of noncash transactions: Finance right-of-use asset obtained in exchange for lease obligations (monoplant) $ 117,622 $ —Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...Instagram:https://instagram. investment property companytxn stock symbolwhat is a steel penny worthbest gold dealer The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an increase of 34.6% to the stock’s current value. caterpillar announcement todayaep dividend Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11. Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...Nov 2, 2023 · Interest income was $4.5 million at September 30, 2023 versus $1.5 million for the prior year period. Interest income was $12.4 million and $2.2 million for the nine months ended September 30 ... forex in usa On today's stock market, AUPH stock toppled 9.4% to 10.49. The hirings likely cooled investors' expectations that Aurinia could be looking for a buyout. In late 2021, reports suggested Bristol ...WebAUPH has no debt and, even better, 400 millions in cash. Good market penetration so far (100 patients Q1, 400 Q2) and guidance provided for the end of the year (40-50 millions) with great expectations for the next years (200 in 2022, 400 in 2023, sales peak at 1.5 billions) ... The short interest. Since the FDA Approval in Jan 2021, the stock ...Despite upbeat remarks from its chief executive ahead of the earnings, Aurinia’s (NASDAQ:AUPH) 2022 sales guidance fell short of expectations as net revenue for the year dropped ~9% YoY to $45 ...